Mood Disorders: Clinical Trials

529 trials for Mood Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

529 completed. 529 Phase 2, 61 Phase 3, 55 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2529Completed 529
Phase 361Completed 61
Phase 155Completed 55

Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders

Trials (filtered) newest first · largest first

All 529 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
Ropanicant, Placebo - Major Depressive Disorder (MDD)
Phase 2CompletedSuven Life Sciences Limited2142025-07-152026-04-07
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder
Phase 2CompletedBioXcel Therapeutics Inc332025-06-192026-10-05
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray - Major Depressive Disorder (MDD
Phase 2CompletedSichuan Purity Pharmaceutical Technology Co., Ltd.982025-05-272026-09-09
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
KH607 tablets, placebo - Major Depressive Disorder (MDD)
Phase 2CompletedChengdu Kanghong Pharmaceutical Group Co., Ltd.1262025-03-192026-07-28
A Study of ONO-1110 in Patients With Major Depressive Disorder
ONO-1110, Placebo - Major Depressive Disorder (MDD
Phase 2CompletedOno Pharmaceutical Co., Ltd.1032025-01-162026-07-08
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
VLS-01-203 BU, VLS-01-BU Placebo - Treatment Resistant Depression
Phase 2Completedatai Therapeutics, Inc.1422024-12-302026-10-30
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
JNJ-89495120, Placebo - Depressive Disorder, Major
Phase 2CompletedJanssen Research & Development, LLC1052024-12-262026-09-25
A Phase II Study to Evaluate NH102 for Depression
NH102, Duloxetine Hydrochloride Enteric-coated Capsule, Placebo - Major Depressive Disorder (MDD)
Phase 2CompletedJiangsu Nhwa Pharmaceutical Co., Ltd.2432024-12-042026-09-22
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers
Psilocybin, Cognitive Behavioral Therapy (CBT) - Major Depressive Disorder
Phase 2CompletedKhyber Medical University Peshawar602024-12-012025-09-02
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
Ketamine, Functional magnetic resonance imaging (fMRI) - Bipolar Depression, Treatment Resistant Bipolar Depression
Phase 2CompletedDrew Cumming202024-11-122026-10-15
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance - Healthy Volunteers
Phase 1 / Phase 2CompletedBiomind Labs Inc.402024-10-212025-03-05
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
ABBV-932, Placebo for ABBV-932 - Bipolar I Disorder, Bipolar II Disorder
Phase 2CompletedAbbVie1612024-10-152026-10-14
A Study to Test Different Doses of BI 1569912 in People With Depression
5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912 - Depressive Disorder, Major
Phase 2CompletedBoehringer Ingelheim2252024-10-012026-05-22
Efficacy of MI078 Capsules in Treating Postpartum Depression
MI078 capsule dose 1, MI078 capsule dose 2, placebo - Postpartum Depression
Phase 2CompletedNanjing Minova Pharmaceutical Co., Ltd.722024-09-092026-06-25
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
BHV-7000 - Major Depressive Disorder
Phase 2CompletedBiohaven Therapeutics Ltd.2332024-08-012026-10-14
Psilocybin for Treatment-Resistant Depression
Psilocybin 25mg, Placebo (active placebo) - Major Depressive Disorder, Anhedonia
Phase 2CompletedUniversity of Colorado, Denver202024-07-082026-05-22
RE104 Safety and Efficacy Study in Postpartum Depression
RE104 for Injection - Postpartum Depression
Phase 2CompletedReunion Neuroscience Inc842024-06-142026-05-14
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
BHV-7000, Placebo - Major Depressive Disorder
Phase 2CompletedBiohaven Therapeutics Ltd.3362024-05-282026-10-14
BHV-7000 Acute Treatment of Bipolar Mania
BHV-7000, Placebo - Bipolar Disorder
Phase 2 / Phase 3CompletedBiohaven Therapeutics Ltd.2742024-05-282025-12-16
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
NMRA-335140 80 mg, Placebo - Major Depressive Episode Associated With Bipolar II Disorder
Phase 2CompletedNeumora Therapeutics, Inc.182024-05-132026-03-30

Showing 20 of 529. Sign in to see all of them.

Narrower conditions

Depressive Disorder, Major (326)  ·  Depression (196)  ·  Bipolar Disorder (115)  ·  Depressive Disorder (76)  ·  Depressive Disorder, Treatment-Resistant (42)  ·  Anxiety Disorders (24)  ·  Depression, Postpartum (22)  ·  Mental Disorders (22)  ·  Psychotic Disorders (22)  ·  Mania (15)  ·  Schizophrenia (15)  ·  Dysthymic Disorder (13)  ·  Alcoholism (11)  ·  Anhedonia (7)

Broader conditions

Mental Disorders (507)  ·  Depressive Disorder (341)  ·  Behavior (212)  ·  Behavioral Symptoms (198)  ·  Bipolar and Related Disorders (115)  ·  Pathological Conditions, Signs and Symptoms (52)  ·  Nervous System Diseases (44)  ·  Signs and Symptoms (40)  ·  Neurologic Manifestations (33)  ·  Neurobehavioral Manifestations (25)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (25)  ·  Urogenital Diseases (25)  ·  Female Urogenital Diseases and Pregnancy Complications (23)  ·  Chemically-Induced Disorders (22)

Interventions

Ketamine (26)  ·  Escitalopram (20)  ·  Sertraline (15)  ·  Psilocybin (14)  ·  Transcranial Direct Current Stimulation (13)  ·  Venlafaxine Hydrochloride (12)  ·  Citalopram (11)  ·  Therapeutics (11)  ·  Cognitive Behavioral Therapy (10)  ·  Fluoxetine (10)  ·  Bupropion (9)  ·  Vortioxetine (8)  ·  Midazolam (7)  ·  Paroxetine (7)  ·  Transcranial Magnetic Stimulation (7)

Sponsors

National Institute of Mental Health (NIMH) (21)  ·  GlaxoSmithKline (14)  ·  Janssen Research & Development, LLC (12)  ·  Massachusetts General Hospital (12)  ·  New York State Psychiatric Institute (10)  ·  University of Pittsburgh (10)  ·  Forest Laboratories (7)  ·  H. Lundbeck A/S (7)  ·  Medical University of South Carolina (7)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (7)  ·  The University of New South Wales (7)  ·  Alto Neuroscience (6)  ·  Mclean Hospital (6)  ·  Sanofi (6)  ·  University of Sao Paulo (6)

Countries

United States (352)  ·  Canada (45)  ·  Germany (32)  ·  Poland (23)  ·  Australia (22)  ·  Russia (22)  ·  United Kingdom (20)  ·  Japan (18)  ·  Bulgaria (16)  ·  China (15)  ·  Spain (13)  ·  Ukraine (13)  ·  Finland (12)  ·  France (11)  ·  Slovakia (11)

Top investigators

Maurizio Fava, MD (6)  ·  Carlos A Zarate, M.D. (4)  ·  Andre R Brunoni, MD (3)  ·  Andrew A Nierenberg, MD (3)  ·  Beth L Murphy, MD, PhD (3)  ·  Ihsan M Salloum, MD, MPH (3)

Results publications

PMID 34510411, PMID 23146246, PMID 27685842, PMID 28086004, PMID 30508090, PMID 31270774, PMID 31969269, PMID 32785636, PMID 32792252, PMID 33128208, PMID 34131914, PMID 34623633, PMID 34817851, PMID 35092868, PMID 37585253, PMID 39240566, PMID 39955416, PMID 40398609, PMID 42304135, PMID 42521762, PMID 42560883, PMID 10197825, PMID 12113998, PMID 12217271, PMID 14557145, PMID 15365580, PMID 15580167, PMID 15583115, PMID 15630071, PMID 15982444, PMID 16319710, PMID 16390366, PMID 16491981, PMID 16894061, PMID 17012684, PMID 17215046, PMID 17690799, PMID 17897484, PMID 18061147, PMID 18295436, PMID 18314433, PMID 18457236, PMID 18480694, PMID 18762591, PMID 18996507, PMID 19182688, PMID 19192466, PMID 19223438, PMID 19254438, PMID 19321268

NIH funding

2015 (5), 2016 (3), 2019 (3), 2008 (2), 2017 (2), 2018 (2), 2023 (2), R33MH122464 (2), U54DA036114 (2), 2009 (1), 2014 (1), 271201100006I-0-27100007-1 (1), K23DA015440 (1), K23MH064528 (1), K23MH066265 (1)